Company: CORT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001628280-25-019942
Chunk: 15

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 15
---
 his or her ability to exercise independent judgment. The Board has determined that the following directors are “independent” under the Nasdaq rules:

<div align='center'>James N. Wilson

Gregg Alton

G. Leonard Baker, Jr.

Gillian M. Cannon

David L. Mahoney

Joshua M. Murray

Kimberly Park

Daniel N. Swisher, Jr.</div>

Dr. Belanoff, our Chief Executive Officer, is an employee and is therefore not “independent.”

In accordance with our Amended and Restated Bylaws, our Board appoints our officers. The Board does not have a policy as to whether the role of the Chairman of the Board and Chief Executive Officer should be separate and whether a lead independent director should be selected. Currently, we separate the roles of Chief Executive Officer and Chairman of the Board. The Chief Executive Officer is responsible for setting Corcept’s strategic direction and its day-to-day leadership and performance. The Chairman of the Board provides guidance to the Chief Executive Officer, sets the agenda for Board meetings and presides over meetings of the full Board. Our Chairman of the Board, Mr. Wilson, is not an employee and is independent. Our Board believes that its leadership is appropriate for Corcept and its stockholders.

Risk Oversight . The Board oversees our exposure to risk and the steps we have undertaken to mitigate those risks. The Board assesses the risks we face and reviews our strategic plan at least annually. The Board also receives regular updates from our Executive Committee, which consists of our Chief Executive Officer, Chief Financial Officer, Chief Accounting & Technology Officer, Chief Business Officer, Chief Development Officer, Chief Human Resources and Communications Officer, Chief Scientific Officer, President, Corcept Endocrinology, President, Corcept Oncology and President, Corcept Emerging Markets, regarding the impact and mitigation of various risks. Although the Board bears ultimate responsibility for the company’s risk management, the Audit Committee oversees management of risks arising from our accounting policies and practices, financial reporting, SEC compliance and potential director or named executive officer conflicts of interest. The Compensation Committee oversees director and executive officer compensation and strives to create compensation incentives that discourage risk-taking inconsistent with our business strategy. The Corporate Governance and Nominating Committee oversees management of risks associated with corporate governance, including environmental and social issues, regulatory compliance and cybersecurity. Each of these committees meets regularly with Corcept management and reports to the full Board.

<div align='center'>9</div>

### COMMUNICATIONS WITH DIRECTORS
Stockholders or other